Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer.

Horn L, Whisenant JG, Wakelee H, Reckamp KL, Qiao H, Leal TA, Du L, Hernandez J, Huang V, Blumenschein GR, Waqar SN, Patel SP, Nieva J, Oxnard GR, Sanborn RE, Shaffer T, Garg K, Holzhausen A, Harrow K, Liang C, Lim LP, Li M, Lovly CM.

J Thorac Oncol. 2019 Aug 22. pii: S1556-0864(19)30665-3. doi: 10.1016/j.jtho.2019.08.003. [Epub ahead of print]

PMID:
31446141
2.

EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.

Rangachari D, To C, Shpilsky JE, VanderLaan PA, Kobayashi SS, Mushajiang M, Lau CJ, Paweletz CP, Oxnard GR, Jänne PA, Costa DB.

J Thorac Oncol. 2019 Aug 1. pii: S1556-0864(19)30599-4. doi: 10.1016/j.jtho.2019.07.016. [Epub ahead of print]

PMID:
31377341
3.

Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA.

Supplee JG, Milan MSD, Lim LP, Potts KT, Sholl LM, Oxnard GR, Paweletz CP.

Lung Cancer. 2019 Aug;134:96-99. doi: 10.1016/j.lungcan.2019.06.004. Epub 2019 Jun 5.

4.

Effective Cancer Genotyping-Many Means to One End.

Meador CB, Oxnard GR.

Clin Cancer Res. 2019 Aug 1;25(15):4583-4585. doi: 10.1158/1078-0432.CCR-19-1233. Epub 2019 May 28.

PMID:
31138589
5.

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.

Li BT, Janku F, Jung B, Hou C, Madwani K, Alden R, Razavi P, Reis-Filho JS, Shen R, Isbell JM, Blocker AW, Eattock N, Gnerre S, Satya RV, Xu H, Zhao C, Hall MP, Hu Y, Sehnert AJ, Brown D, Ladanyi M, Rudin CM, Hunkapiller N, Feeney N, Mills GB, Paweletz CP, Janne PA, Solit DB, Riely GJ, Aravanis A, Oxnard GR.

Ann Oncol. 2019 Apr 1;30(4):597-603. doi: 10.1093/annonc/mdz046.

PMID:
30891595
6.

Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer.

Blumenthal GM, Gong Y, Kehl K, Mishra-Kalyani P, Goldberg KB, Khozin S, Kluetz PG, Oxnard GR, Pazdur R.

Ann Oncol. 2019 May 1;30(5):830-838. doi: 10.1093/annonc/mdz060.

PMID:
30796424
7.

Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology.

Dercle L, Connors DE, Tang Y, Adam SJ, Gönen M, Hilden P, Karovic S, Maitland M, Moskowitz CS, Kelloff G, Zhao B, Oxnard GR, Schwartz LH.

JCO Clin Cancer Inform. 2018 Dec;2:1-12. doi: 10.1200/CCI.17.00137.

8.

Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions.

Piotrowska Z, Costa DB, Oxnard GR, Huberman M, Gainor JF, Lennes IT, Muzikansky A, Shaw AT, Azzoli CG, Heist RS, Sequist LV.

Ann Oncol. 2018 Oct 1;29(10):2092-2097. doi: 10.1093/annonc/mdy336.

PMID:
30351341
9.

Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing.

Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, Sonpavde G, Lee CE, Lanman RB, Meric-Bernstam F, Kurzrock R, Weitzel JN.

J Clin Oncol. 2018 Oct 19:JCO1800328. doi: 10.1200/JCO.18.00328. [Epub ahead of print]

PMID:
30339520
10.

Precision Medicine in Non-Small Cell Lung Cancer: Current Standards in Pathology and Biomarker Interpretation.

Brown NA, Aisner DL, Oxnard GR.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:708-715. doi: 10.1200/EDBK_209089. Review.

PMID:
30231309
11.

Does TMB Impact the Effectiveness of TKIs in EGFR-Mutant NSCLC?

Cheng ML, Oxnard GR.

Clin Cancer Res. 2019 Feb 1;25(3):899-900. doi: 10.1158/1078-0432.CCR-18-2368. Epub 2018 Sep 6.

PMID:
30190372
12.

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.

Jorge SE, Lucena-Araujo AR, Yasuda H, Piotrowska Z, Oxnard GR, Rangachari D, Huberman MS, Sequist LV, Kobayashi SS, Costa DB.

Clin Cancer Res. 2018 Dec 15;24(24):6548-6555. doi: 10.1158/1078-0432.CCR-18-1541. Epub 2018 Aug 28.

PMID:
30154228
13.

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.

Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, Kwiatkowski DJ, Rabin MS, Paweletz CP, Thress KS, Jänne PA.

JAMA Oncol. 2018 Nov 1;4(11):1527-1534. doi: 10.1001/jamaoncol.2018.2969.

14.

Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping.

Guibert N, Tsukada H, Hwang DH, Chambers E, Cibas ES, Bale T, Supplee J, Ulrich B, Sholl LM, Paweletz CP, Oxnard GR.

Lung Cancer. 2018 Aug;122:72-75. doi: 10.1016/j.lungcan.2018.05.024. Epub 2018 May 25.

PMID:
30032849
15.

Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays.

Oxnard GR, Paweletz CP.

JAMA Oncol. 2018 Oct 1;4(10):1428-1429. doi: 10.1001/jamaoncol.2018.2311. No abstract available.

PMID:
30027282
16.

Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors.

Camidge DR, Sequist LV, Jänne PA, Weickhardt AJ, Dowling ES, Alicea J, Fan J, Oxnard GR.

Clin Lung Cancer. 2018 Sep;19(5):e655-e665. doi: 10.1016/j.cllc.2018.04.015. Epub 2018 May 5.

PMID:
29861396
17.

Monitoring of Response and Resistance in Plasma of EGFR-Mutant Lung Cancer Using Droplet Digital PCR.

Kuang Y, O'Connell A, Sacher AG, Feeney N, Alden RS, Oxnard GR, Paweletz CP.

Methods Mol Biol. 2018;1768:193-207. doi: 10.1007/978-1-4939-7778-9_12.

PMID:
29717445
18.

False-Positive Plasma Genotyping Due to Clonal Hematopoiesis.

Hu Y, Ulrich BC, Supplee J, Kuang Y, Lizotte PH, Feeney NB, Guibert NM, Awad MM, Wong KK, Jänne PA, Paweletz CP, Oxnard GR.

Clin Cancer Res. 2018 Sep 15;24(18):4437-4443. doi: 10.1158/1078-0432.CCR-18-0143. Epub 2018 Mar 22.

19.

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.

Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC.

J Clin Oncol. 2018 Jun 1;36(16):1631-1641. doi: 10.1200/JCO.2017.76.8671. Epub 2018 Mar 5. Review.

PMID:
29504847
20.

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.

Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC.

Arch Pathol Lab Med. 2018 Oct;142(10):1242-1253. doi: 10.5858/arpa.2018-0901-SA. Epub 2018 Mar 5. Review.

PMID:
29504834
21.

Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.

Guibert N, Hu Y, Feeney N, Kuang Y, Plagnol V, Jones G, Howarth K, Beeler JF, Paweletz CP, Oxnard GR.

Ann Oncol. 2018 Apr 1;29(4):1049-1055. doi: 10.1093/annonc/mdy005.

22.

A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.

Yu HA, Spira A, Horn L, Weiss J, West H, Giaccone G, Evans T, Kelly RJ, Desai B, Krivoshik A, Moran D, Poondru S, Jie F, Aoyama K, Keating A, Oxnard GR.

Clin Cancer Res. 2017 Dec 15;23(24):7467-7473. doi: 10.1158/1078-0432.CCR-17-1447. Epub 2017 Sep 27.

23.

Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients.

Hu Y, Alden RS, Odegaard JI, Fairclough SR, Chen R, Heng J, Feeney N, Nagy RJ, Shah J, Ulrich B, Gutierrez M, Lanman RB, Garber JE, Paweletz CP, Oxnard GR.

Clin Cancer Res. 2017 Dec 1;23(23):7351-7359. doi: 10.1158/1078-0432.CCR-17-1745. Epub 2017 Sep 25.

24.

Application of Plasma Genotyping Technologies in Non-Small Cell Lung Cancer: A Practical Review.

Sacher AG, Komatsubara KM, Oxnard GR.

J Thorac Oncol. 2017 Sep;12(9):1344-1356. doi: 10.1016/j.jtho.2017.05.022. Epub 2017 Jun 10. Review.

25.

Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer.

Leonardi GC, Oxnard GR, Haas A, Lang JP, Williams JS, Awad MM.

J Immunother. 2017 Jul/Aug;40(6):249-251. doi: 10.1097/CJI.0000000000000173.

PMID:
28557813
26.

Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Non-Small-Cell Lung Cancer With Brain Metastases.

Martínez P, Mak RH, Oxnard GR.

JAMA Oncol. 2017 Sep 1;3(9):1274-1275. doi: 10.1001/jamaoncol.2017.1047. Review.

PMID:
28520828
27.

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.

Kosaka T, Tanizaki J, Paranal RM, Endoh H, Lydon C, Capelletti M, Repellin CE, Choi J, Ogino A, Calles A, Ercan D, Redig AJ, Bahcall M, Oxnard GR, Eck MJ, Jänne PA.

Cancer Res. 2017 May 15;77(10):2712-2721. doi: 10.1158/0008-5472.CAN-16-3404. Epub 2017 Mar 31.

28.

Corrigendum: Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC.

Aerts HJ, Grossmann P, Tan Y, Oxnard GR, Rizvi N, Schwartz LH, Zhao B.

Sci Rep. 2017 Feb 17;7:41197. doi: 10.1038/srep41197. No abstract available.

29.

Institutional implementation of clinical tumor profiling on an unselected cancer population.

Sholl LM, Do K, Shivdasani P, Cerami E, Dubuc AM, Kuo FC, Garcia EP, Jia Y, Davineni P, Abo RP, Pugh TJ, van Hummelen P, Thorner AR, Ducar M, Berger AH, Nishino M, Janeway KA, Church A, Harris M, Ritterhouse LL, Campbell JD, Rojas-Rudilla V, Ligon AH, Ramkissoon S, Cleary JM, Matulonis U, Oxnard GR, Chao R, Tassell V, Christensen J, Hahn WC, Kantoff PW, Kwiatkowski DJ, Johnson BE, Meyerson M, Garraway LA, Shapiro GI, Rollins BJ, Lindeman NI, MacConaill LE.

JCI Insight. 2016 Nov 17;1(19):e87062. doi: 10.1172/jci.insight.87062.

30.

Restoring Balance: Paraneoplastic Cerebellar Degeneration.

Klein JP, Stover DG, Oxnard GR, Levy BD, Loscalzo J.

Am J Med. 2017 Mar;130(3):e85-e87. doi: 10.1016/j.amjmed.2016.09.035. Epub 2016 Nov 2. No abstract available.

PMID:
27816447
31.

Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.

Bahcall M, Sim T, Paweletz CP, Patel JD, Alden RS, Kuang Y, Sacher AG, Kim ND, Lydon CA, Awad MM, Jaklitsch MT, Sholl LM, Jänne PA, Oxnard GR.

Cancer Discov. 2016 Dec;6(12):1334-1341. Epub 2016 Sep 30.

32.

Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC.

Aerts HJ, Grossmann P, Tan Y, Oxnard GR, Rizvi N, Schwartz LH, Zhao B.

Sci Rep. 2016 Sep 20;6:33860. doi: 10.1038/srep33860. Erratum in: Sci Rep. 2017 Feb 17;7:41197.

33.

Genomic Analysis of Plasma Cell-Free DNA in Patients With Cancer.

Oxnard GR, Paweletz CP, Sholl LM.

JAMA Oncol. 2017 Jun 1;3(6):740-741. doi: 10.1001/jamaoncol.2016.2835. No abstract available.

PMID:
27541382
34.

Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development.

Lampson BL, Nishino M, Dahlberg SE, Paul D, Santos AA, Jänne PA, Oxnard GR.

Cancer. 2016 Nov 15;122(22):3456-3463. doi: 10.1002/cncr.30270. Epub 2016 Aug 15.

35.

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.

Reckamp KL, Melnikova VO, Karlovich C, Sequist LV, Camidge DR, Wakelee H, Perol M, Oxnard GR, Kosco K, Croucher P, Samuelsz E, Vibat CR, Guerrero S, Geis J, Berz D, Mann E, Matheny S, Rolfe L, Raponi M, Erlander MG, Gadgeel S.

J Thorac Oncol. 2016 Oct;11(10):1690-700. doi: 10.1016/j.jtho.2016.05.035. Epub 2016 Jul 25.

36.

Early Intervention in Lung Cancers With Rapid Plasma Genotyping for EGFR and KRAS Mutations-Reply.

Sacher AG, Alden RS, Oxnard GR.

JAMA Oncol. 2016 Aug 1;2(8):1096-7. doi: 10.1001/jamaoncol.2016.1963. No abstract available.

PMID:
27388452
37.

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, Yang JC, Barrett JC, Jänne PA.

J Clin Oncol. 2016 Oct 1;34(28):3375-82. doi: 10.1200/JCO.2016.66.7162. Epub 2016 Jun 27.

38.

A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.

Yanagita M, Redig AJ, Paweletz CP, Dahlberg SE, O'Connell A, Feeney N, Taibi M, Boucher D, Oxnard GR, Johnson BE, Costa DB, Jackman DM, Jänne PA.

Clin Cancer Res. 2016 Dec 15;22(24):6010-6020. Epub 2016 Jun 8.

39.

Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.

Sacher AG, Paweletz C, Dahlberg SE, Alden RS, O'Connell A, Feeney N, Mach SL, Jänne PA, Oxnard GR.

JAMA Oncol. 2016 Aug 1;2(8):1014-22. doi: 10.1001/jamaoncol.2016.0173. Erratum in: JAMA Oncol. 2016 Aug 1;2(8):1099.

40.

The cellular origins of drug resistance in cancer.

Oxnard GR.

Nat Med. 2016 Mar;22(3):232-4. doi: 10.1038/nm.4058. No abstract available.

PMID:
26937615
41.

Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.

Oxnard GR, Wilcox KH, Gonen M, Polotsky M, Hirsch BR, Schwartz LH.

JAMA Oncol. 2016 Jun 1;2(6):772-9. doi: 10.1001/jamaoncol.2015.6315.

42.

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.

Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, Heng JC, Dahlberg SE, Jänne PA, Verma S, Christensen J, Hammerman PS, Sholl LM.

J Clin Oncol. 2016 Mar 1;34(7):721-30. doi: 10.1200/JCO.2015.63.4600. Epub 2016 Jan 4.

PMID:
26729443
43.

Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.

Sacher AG, Dahlberg SE, Heng J, Mach S, Jänne PA, Oxnard GR.

JAMA Oncol. 2016 Mar;2(3):313-20. doi: 10.1001/jamaoncol.2015.4482.

44.

ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.

Govindan R, Mandrekar SJ, Gerber DE, Oxnard GR, Dahlberg SE, Chaft J, Malik S, Mooney M, Abrams JS, Jänne PA, Gandara DR, Ramalingam SS, Vokes EE.

Clin Cancer Res. 2015 Dec 15;21(24):5439-44. doi: 10.1158/1078-0432.CCR-15-0354. Review.

45.

Clinical Implications of Variant ALK FISH Rearrangement Patterns.

Gao X, Sholl LM, Nishino M, Heng JC, Jänne PA, Oxnard GR.

J Thorac Oncol. 2015 Nov;10(11):1648-52. doi: 10.1097/JTO.0000000000000665.

46.

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.

Calles A, Liao X, Sholl LM, Rodig SJ, Freeman GJ, Butaney M, Lydon C, Dahlberg SE, Hodi FS, Oxnard GR, Jackman DM, Jänne PA.

J Thorac Oncol. 2015 Dec;10(12):1726-35. doi: 10.1097/JTO.0000000000000687.

47.

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.

Paweletz CP, Sacher AG, Raymond CK, Alden RS, O'Connell A, Mach SL, Kuang Y, Gandhi L, Kirschmeier P, English JM, Lim LP, Jänne PA, Oxnard GR.

Clin Cancer Res. 2016 Feb 15;22(4):915-22. doi: 10.1158/1078-0432.CCR-15-1627-T. Epub 2015 Oct 12.

48.

Biomarker-driven adjuvant targeted therapy for NSCLC-the ALCHEMIST trials.

Oxnard GR, Watt C, Wigle D, Boughey JC.

Bull Am Coll Surg. 2015 Sep;100(9):25-7. No abstract available.

PMID:
26455072
49.

Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.

Alden RS, Mandrekar SJ, Oxnard GR.

Chin Clin Oncol. 2015 Sep;4(3):37. doi: 10.3978/j.issn.2304-3865.2015.09.03. Review.

50.

Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.

Tanizaki J, Ercan D, Capelletti M, Dodge M, Xu C, Bahcall M, Tricker EM, Butaney M, Calles A, Sholl LM, Hammerman PS, Oxnard GR, Wong KK, Jänne PA.

Cancer Res. 2015 Aug 1;75(15):3139-46. doi: 10.1158/0008-5472.CAN-14-3771. Epub 2015 Jun 5.

Supplemental Content

Loading ...
Support Center